Big Pharma's now got a one-person play called...Big Pharma...! in which writer-director-actor Jennifer Berry apparently skewers said industry. How many plays get reviewed by both the LA Weekly and PLOS Biology? Read on...
Vermont officials said drug company payments to psychiatrists in the state averaged $45,692 EACH!, up from $20,835 in 2005; this doesn't include drug samples...
Medical dictionary, ICD-9 codes, pharmaceutical companies, medical abbreviations, hospitals and associations. Plus medical news and other searches for the medical, pharmaceutical or healthcare professional.
"Pharma 2020: The Vision - Which Path Will You Take? indicates that the current pharmaceutical industry business model is both economically unsustainable and operationally incapable of acting quickly enough"
Provides information on the patient assistance programs that are established by prescription drug manufacturers. These programs are designed to help those who can't afford their medicines obtain them at no cost or low cost...
RxNorm, a standardized nomenclature for clinical drugs, is produced by the National Library of Medicine (NLM). In this context, a clinical drug is a pharmaceutical product given to (or taken by) a patient with a therapeutic or diagnostic intent. In RxNorm
There are thousands of promising drugs for treating diseases that are simply not getting studied or brought to market because they are derived from natural or common substances that can't be patented. The dirty little secret of the pharma business is that
After participating in this activity, participants should be better able to: Review the epidemiology and pathogenesis of acute bronchitis, including a discussion of the bacteriologic etiology. Discuss clinical features that are diagnostic of acute bro
German drugmaker Boehringer Ingelheim didn't set out to create a Viagra-like drug for women. The company was simply trying to develop a fast-acting antidepressant, one that patients would respond to in a matter of days, not weeks as in most current treatm
Despite 15 years as a cancer doctor and researcher, I struggle several times each week to endure the hardest part of my job – walking into a patient's room to helplessly watch as cancer steals away their life and torments them and their loved ones...we
Big Pharma is also showing interest for this emerging market and an example which illustrates this attention is the deal that Merck KGaA has just signed with Chi-Med under which the German drugmaker will develop new cancer treatments using traditional Chi